Payment overview · 2025
General Payments
$520.57
30 reported records · 8 companies
Healthcare provider profile · identity verified
Nancy Finnerty, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DADE CITY, FL · NPI 1275554412
Verified facts
What the public records show
CMS Open Payments records show Nancy Finnerty, MD received $520.57 in general payments during 2025 across 30 reported records.
Amgen Inc. accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $138.40 | 26.6% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $96.54 | 18.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $95.89 | 18.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.04 | 13.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.95 | 11.1% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.78 | 5.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.44 | 3.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.53 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $520.57 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $128.41 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $109.63 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $81.17 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $71.04 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.36 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.53 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.27 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.27 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $9.99 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $9.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 34 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 538 | 152 |
| Lisinopril | Lisinopril | 386 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 81 |
| Omeprazole | Omeprazole | 309 | 82 |
| Losartan Potassium | Losartan Potassium | 263 | 71 |
| Alprazolam | Alprazolam | 217 | 52 |
| Simvastatin | Simvastatin | 192 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 186 | 55 |
| Gabapentin | Gabapentin | 163 | 56 |
| Oxycodone Hcl | Oxycodone Hcl | 161 | 31 |
| Tramadol Hcl | Tramadol Hcl | 161 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 49 |
| Metformin Hcl | Metformin Hcl | 140 | 45 |
| Furosemide | Furosemide | 137 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 34 |
| Celecoxib | Celecoxib | 116 | 34 |
| Montelukast Sodium | Montelukast Sodium | 115 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 37 |
| Baclofen | Baclofen | 110 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 32 |
| Trazodone Hcl | Trazodone Hcl | 101 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 31 |
| Prednisone | Prednisone | 95 | 71 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 23 |
| Fenofibrate | Fenofibrate | 86 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 29 |
| Metformin Hcl Er | Metformin Hcl | 83 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 30 |
| Pregabalin | Pregabalin | 82 | 30 |
| Meloxicam | Meloxicam | 76 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 20 |
| Lorazepam | Lorazepam | 74 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 24 |
| Naproxen | Naproxen | 73 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 68 | 12 |
| Allopurinol | Allopurinol | 67 | 20 |
| Potassium Chloride | Potassium Chloride | 62 | 17 |
| Famotidine | Famotidine | 60 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 22 |
| Sertraline Hcl | Sertraline Hcl | 58 | 17 |
| Carvedilol | Carvedilol | 57 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 19 |
| Glipizide | Glipizide | 54 | 15 |
| Atenolol | Atenolol | 51 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 19 |
| Glipizide Er | Glipizide | 51 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 11 |
| Ezetimibe | Ezetimibe | 35 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 14 |
| Eliquis | Apixaban | 34 | 12 |
| Meclizine Hcl | Meclizine Hcl | 34 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 28 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | 11 |
| Spironolactone | Spironolactone | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 22 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 14 |
| Topiramate | Topiramate | 23 | suppressed |
| Xtampza Er | Oxycodone Myristate | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $520.57 · 30 records | Amgen Inc. | CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, PROLIA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error